OSA is categorized by severity, and mild sleep apnea can often be minimized through lifestyle changes. Quitting smoking and ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

Tirzepatide is the active ingredient in Zepbound, the FDA approved prescription medicine for Obstructive Sleep Apnea.

Sleep apnea affects millions globally, often lurking undetected until it begins impacting overall health. While high blood ...

Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, ...

Estimated 54 million people suffer from obstructive sleep apnea in the U.S. including 30-50% of adults with hypertension, both conditions associated with excess morbidity and mortality – – Obstructive ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

"For obese individuals with moderate to severe sleep apnea, this new treatment option ... given that loud snoring and gasping for air are primary symptoms," she said. Dr. William Lu, medical ...

FDA approves Zepbound for obstructive sleep apnea in obese individuals Discover how this weight-loss drug reduces symptoms ...

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical ...